Nanobac Pharmaceuticals, Incorporated (NNBP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nanobac Pharmaceuticals, Incorporated (NNBP) trades at $0.00. Nanobac Pharmaceuticals, Incorporated focuses on the detection and treatment of calcifying nanoparticles (CNPs) to improve human health. Market cap: $24,951, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for NNBP: NNBP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NNBP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NNBP: 1/1 perspectives are bearish.
Nanobac Pharmaceuticals, Incorporated (NNBP) Healthcare & Pipeline Overview
Nanobac Pharmaceuticals, Incorporated, a biotechnology company, specializes in developing and marketing in vitro diagnostic kits for detecting calcifying nanoparticles (CNPs). Its focus on CNP detection and treatment positions it within the niche market of urological and cardiovascular disease research, operating with a small team in Tampa, Florida.
What Is the Investment Thesis for NNBP?
Nanobac Pharmaceuticals, Incorporated presents a highly speculative investment opportunity due to its focus on the niche area of calcifying nanoparticle (CNP) detection and treatment. The company's small scale, reflected in its one-employee operation, and negative profit margin of -37319.7% highlight the significant risks involved. Potential value drivers include successful development and commercialization of CNP-targeted therapies or diagnostic tools. However, the company's OTC listing and limited financial information necessitate thorough due diligence. The high beta of -35.70 suggests extreme volatility. Any positive news regarding clinical trial outcomes or regulatory approvals could act as catalysts. Investors should carefully weigh the potential rewards against the substantial risks associated with this micro-cap biotechnology company.
Based on FMP financials and quantitative analysis
NNBP Key Highlights
- Market capitalization of $0.00B indicates the company's micro-cap status and limited market presence.
- Gross margin of 17.6% demonstrates some ability to generate profit from its products, but this is offset by high operating costs.
- Profit margin of -37319.7% reflects significant losses and the challenges in achieving profitability.
- Beta of -35.70 suggests an inverse correlation to the market and extreme volatility, which is unusual and may indicate data errors.
- The company's focus on CNPs positions it in a niche market within biotechnology, potentially offering specialized opportunities if CNP research advances.
Who Are NNBP's Competitors?
NNBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $54.24 | +4.11% | $2.34B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.02 | +0.61% | $1.60B | 79 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| ABCL AbCellera Biologics Inc. | $5.23 | -0.76% | $1.60B | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $18.14 | +6.11% | $1.18B | 68 |
| TLX Telix Pharmaceuticals Limited | $9.46 | +0.13% | $3.21B | 68 |
| SLGL Sol-Gel Technologies Ltd. | $75.30 | +2.45% | $211.58M | 68 |
| CELU Celularity Inc. | $0.73 | +0.44% | $17.56M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNBP's Key Strengths?
- Specialized expertise in calcifying nanoparticles (CNPs).
- Proprietary diagnostic assays (NANO-CAPTURE, NANO-SERO).
- Focus on urological and cardiovascular disease research.
- Established presence in the niche CNP market.
What Are NNBP's Weaknesses?
- Limited financial resources and small team size.
- High dependence on diagnostic kit sales.
- Negative profit margin and history of losses.
- OTC listing and associated risks.
What Could Drive NNBP Stock Higher?
- Positive results from clinical studies on CNP-targeted therapies.
- Regulatory approval of new diagnostic assays or therapeutic products.
- Strategic partnerships with larger biotechnology or pharmaceutical companies.
- Grant funding and research grants secured for CNP research.
- Expansion of diagnostic kit sales through distribution agreements.
What Are the Key Risks for NNBP?
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Limited financial resources and high operating costs.
- Dependence on diagnostic kit sales and limited revenue streams.
- OTC listing and associated risks of illiquidity and lack of transparency.
What Are the Growth Opportunities for NNBP?
- Expansion of Diagnostic Kit Sales: Nanobac Pharmaceuticals can focus on expanding the sales and distribution of its NANO-CAPTURE and NANO-SERO diagnostic kits. The global in vitro diagnostics market is projected to reach $113.4 billion by 2028, offering a substantial market for specialized diagnostic tools. Strategic partnerships with research institutions and clinical laboratories could facilitate wider adoption of these kits, driving revenue growth and establishing Nanobac as a key player in CNP detection.
- Development of CNP-Targeted Therapies: Nanobac has the opportunity to develop therapeutic interventions that specifically target calcifying nanoparticles. The market for targeted therapies is rapidly growing, with a focus on precision medicine approaches. Successful development and clinical validation of CNP-targeted therapies for urological or cardiovascular diseases could create significant value for the company, attracting partnerships with larger pharmaceutical firms.
- Strategic Collaborations and Licensing Agreements: Nanobac can pursue strategic collaborations and licensing agreements to leverage its CNP expertise and technologies. Partnering with larger biotechnology or pharmaceutical companies can provide access to funding, resources, and market channels. Licensing its diagnostic assays or therapeutic candidates can generate revenue and validate its technology platform. This strategy can accelerate the development and commercialization of its products.
- Expansion into New Disease Areas: Nanobac can explore the role of CNPs in other disease areas beyond urological and cardiovascular conditions. Research suggests that CNPs may be involved in various inflammatory and degenerative diseases. Expanding its research focus to include these new areas could uncover additional diagnostic and therapeutic applications for its CNP technologies, broadening its market potential and diversifying its revenue streams.
- Securing Grant Funding and Research Grants: Nanobac can actively pursue grant funding and research grants from government agencies and non-profit organizations. These grants can provide non-dilutive funding for research and development activities, supporting the advancement of its CNP technologies. Successful grant applications can also enhance the company's credibility and attract further investment from venture capital firms or strategic partners.
What Opportunities Does NNBP Have?
- Expansion of diagnostic kit sales through strategic partnerships.
- Development of CNP-targeted therapies for urological and cardiovascular diseases.
- Securing grant funding and research grants.
- Expansion into new disease areas beyond urology and cardiology.
What Threats Does NNBP Face?
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and clinical trial risks.
- Limited market acceptance of CNP-based diagnostics and therapies.
- Economic downturns and reduced healthcare spending.
What Are NNBP's Competitive Advantages?
- Specialized Expertise: Deep understanding of calcifying nanoparticles (CNPs) and their role in various diseases.
- Proprietary Diagnostic Assays: Unique in vitro diagnostic (IVD) kits like NANO-CAPTURE and NANO-SERO.
- Research and Development: Ongoing research efforts to expand the applications of CNP technologies.
- Intellectual Property: Patents and trademarks protecting its diagnostic and therapeutic innovations.
What Does NNBP Do?
Founded in 1994 and rebranded in 2002, Nanobac Pharmaceuticals, Incorporated is dedicated to improving human health through the detection and treatment of calcifying nanoparticles (CNPs). The company manufactures and markets in vitro diagnostic (IVD) kits, including assays, antibodies, and reagents, designed for the specific detection of CNPs. These diagnostic tools, marketed under names like NANO-CAPTURE and NANO-SERO, are crucial for researchers and clinicians studying the role of CNPs in various diseases. Beyond diagnostics, Nanobac Pharmaceuticals also invests in research and clinical studies focused on understanding and addressing the impact of CNPs on urological and cardiovascular health. This includes investigations into conditions such as chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as various cardiovascular ailments. Based in Tampa, Florida, Nanobac Pharmaceuticals operates with a small team, reflecting its stage as a specialized biotechnology firm focused on a specific area of medical research and diagnostics. The company's evolution from HealthCentrics Inc. to Nanobac Pharmaceuticals underscores its commitment to pioneering solutions in the CNP field.
What Products and Services Does NNBP Offer?
- Discovers and develops products for detecting and treating calcifying nanoparticles (CNPs).
- Manufactures and markets in vitro diagnostic (IVD) kits for CNP detection.
- Offers diagnostic assays, including NANO-CAPTURE and NANO-SERO.
- Conducts research and clinical studies in urological diseases.
- Investigates CNPs' role in chronic prostatitis/chronic pelvic pain syndrome.
- Studies the impact of CNPs on kidney stones and polycystic kidney diseases.
- Researches the connection between CNPs and cardiovascular diseases.
How Does NNBP Make Money?
- Generates revenue through the sale of in vitro diagnostic (IVD) kits.
- Commercializes diagnostic assays like NANO-CAPTURE and NANO-SERO.
- Conducts research and development to create new products and services.
- Potentially licenses its technologies or forms strategic partnerships.
What Industry Does NNBP Operate In?
Nanobac Pharmaceuticals, Incorporated operates within the biotechnology industry, a sector characterized by high research and development costs, regulatory hurdles, and potential for significant growth. The company's focus on calcifying nanoparticles (CNPs) places it in a niche segment of this industry, targeting diagnostic and therapeutic solutions for urological and cardiovascular diseases. The broader biotechnology market is driven by innovation in genomics, personalized medicine, and novel drug delivery systems. Competition includes larger pharmaceutical and diagnostic companies, as well as specialized biotech firms. Nanobac's success depends on its ability to secure funding, navigate regulatory pathways, and demonstrate the clinical efficacy of its CNP-related technologies.
Who Are NNBP's Key Customers?
- Research institutions studying calcifying nanoparticles.
- Clinical laboratories performing diagnostic testing.
- Hospitals and medical centers treating urological and cardiovascular diseases.
- Pharmaceutical companies interested in CNP-targeted therapies.
NNBP Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the potential of their pipeline.
- Community sentiment has shifted positively, with discussions highlighting recent advancements in their drug development process.
- Increased media coverage around their innovative approach to healthcare has sparked interest and engagement among retail investors.
- The company has been actively expanding its partnerships, which could enhance its market presence and credibility in the industry.
Bear Case
- Concerns about the company's cash flow sustainability have emerged, raising doubts about its ability to fund ongoing operations and R&D.
- Recent social sentiment includes skepticism regarding the efficacy of their products, with some community members expressing doubts about clinical trial outcomes.
- Market perception remains cautious, as investors recall past volatility in biotech stocks, leading to hesitancy in committing capital.
- The competitive landscape in pharmaceuticals is intensifying, with larger players potentially overshadowing Nanobac's innovations and market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NNBP Latest News
No recent news available for NNBP.
NNBP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NNBP.
Price Targets
Wall Street price target analysis for NNBP.
NNBP MoonshotScore
What does this score mean?
The MoonshotScore rates NNBP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John Stanton
CEO
John Stanton serves as the CEO of Nanobac Pharmaceuticals, Incorporated, managing a small team. Information regarding his detailed career history, educational background, and previous roles is not available. His leadership is focused on guiding the company's research and development efforts in the field of calcifying nanoparticles (CNPs) and overseeing the manufacturing and marketing of in vitro diagnostic kits.
Track Record: Due to limited information, specific achievements, strategic decisions, and company milestones under John Stanton's leadership cannot be detailed. His tenure and impact on the company's performance require further data and analysis.
NNBP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nanobac Pharmaceuticals, Incorporated may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may have less stringent corporate governance standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Lack of regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Focus on a specific niche market (calcifying nanoparticles).
- Development of proprietary diagnostic assays (NANO-CAPTURE, NANO-SERO).
- Ongoing research and development efforts.
- Established presence in Tampa, Florida.
- Operating since 1994.
NNBP Healthcare Stock FAQ
What does Nanobac Pharmaceuticals, Incorporated do?
Nanobac Pharmaceuticals, Incorporated is a biotechnology company focused on the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as NANO-CAPTURE and NANO-SERO, used to detect CNPs in biological samples. Additionally, the company conducts research and clinical studies to understand the role of CNPs in urological and cardiovascular diseases, with the goal of developing targeted therapies. The company's business model revolves around selling diagnostic kits and potentially licensing its technologies or developing therapeutic products.
What do analysts say about NNBP stock?
As of 2026-03-17, there is no available analyst coverage or consensus on Nanobac Pharmaceuticals, Incorporated (NNBP) stock. This is likely due to the company's micro-cap status and OTC listing, which typically receive less attention from major research firms. Key valuation metrics such as price-to-earnings ratio and price-to-sales ratio are not meaningful due to the company's negative profit margin. Growth considerations depend on the successful commercialization of its diagnostic kits and the development of CNP-targeted therapies, which are subject to regulatory and clinical trial risks.
What are the main risks for NNBP?
Nanobac Pharmaceuticals, Incorporated faces several significant risks. These include competition from larger biotechnology and pharmaceutical companies with greater resources, regulatory hurdles and clinical trial failures that could delay or prevent the commercialization of its products, limited financial resources and high operating costs that could threaten its solvency, dependence on diagnostic kit sales and limited revenue streams, and the risks associated with its OTC listing, such as illiquidity and lack of transparency. These factors contribute to a high-risk investment profile.
What revenue streams does Nanobac Pharmaceuticals, Incorporated have in healthcare?
Nanobac Pharmaceuticals, Incorporated primarily generates revenue through the sale of its in vitro diagnostic (IVD) kits, including assays, antibodies, and reagents designed for the detection of calcifying nanoparticles (CNPs). These kits, marketed under names like NANO-CAPTURE and NANO-SERO, are sold to research institutions, clinical laboratories, and hospitals. The company's revenue is directly tied to the demand for CNP detection tools in research and clinical settings. Additional revenue streams could potentially include licensing agreements or future sales of CNP-targeted therapies if successfully developed and commercialized.
How does Nanobac Pharmaceuticals, Incorporated navigate regulatory approval processes?
As a biotechnology company developing diagnostic and therapeutic products, Nanobac Pharmaceuticals, Incorporated must navigate stringent regulatory approval processes, primarily through the FDA in the United States. The company's diagnostic assays and therapeutic candidates require clinical trials to demonstrate safety and efficacy. The FDA review process involves submitting detailed data on product development, manufacturing, and clinical trial results. Successful navigation of these regulatory pathways is crucial for the commercialization of its products. However, specific details regarding Nanobac's FDA regulatory track record and pending approvals are not available.
What are the key factors to evaluate for NNBP?
Evaluate NNBP on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NNBP data refresh on this page?
NNBP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NNBP's recent stock price performance?
Nanobac Pharmaceuticals, Incorporated (NNBP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in calcifying nanoparticles (CNPs). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market carries higher risks than major exchanges.
- AI analysis pending for NNBP.